Impact of angiotensin receptor blockers on mortality after hospitalization for symptomatic lower extremity artery disease
- 9 April 2020
- journal article
- research article
- Published by Oxford University Press (OUP) in European Heart Journal - Cardiovascular Pharmacotherapy
- Vol. 7 (6), 463-474
- https://doi.org/10.1093/ehjcvp/pvaa026
Abstract
The objective was to assess the association between angiotensin-converting-enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB) prescription at discharge in patients hospitalized for symptomatic lower extremity artery disease (LEAD) and one-year mortality. The COPART registry is a multicentre, prospective, observational, cohort study which includes consecutive patients hospitalized for symptomatic LEAD in 4 French academic centres. All-cause mortality during a one-year follow-up after hospital discharge was compared between patients with ARB, patients with ACEI and patients without ARB or ACEI. Analyses were performed using Cox models. As a sensitivity analysis, a propensity score (PS)-matching analysis was carried out. Among 1,981 patients, 421 had ARB (21.3%), 766 ACEI (38.7%), and 794 no ACEI/ARB (40.1%) at discharge. During the one-year follow-up, incidence rates for mortality were 12.6/100 person-years (95% confidence interval, 9.7-16.1) for patients with ARB, 15.8/100 person-years (95%CI, 13.4-18.6) for patients with ACEI and 19.8/100 person-years for patients without ACEI/ARB (95%CI, 17.2-22.8). In a multivariate Cox model, ARB at discharge was associated with decreased mortality compared with no ACEI/ARB, hazard ratio (HR) 0.68 (95%CI, 0.49-0.95), and with ACEI, HR 0.69 (95%CI, 0.49-0.97). These results are consistent with those obtained by the Cox analyses in the PS-matched sample: HR 0.68 (95%CI, 0.47-0.98) for patients with ARB compared with no ARB. ARB at discharge after hospitalization for symptomatic LEAD is associated with a better survival compared with ACEI or no ACEI/ARB.Keywords
Funding Information
- Bayer Healthcare and BMS/Pfizer
- Astra-Zeneca
- Bayer Healthcare, BMS/Pfizer, Novartis, and Sanofi
This publication has 20 references indexed in Scilit:
- Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers in Patients Without Heart Failure? Insights From 254,301 Patients From Randomized TrialsMayo Clinic Proceedings, 2016
- Angiotensin converting enzyme (ACE) inhibitors versus angiotensin receptor blockers for primary hypertensionEmergencias, 2014
- Peripheral artery disease is a coronary heart disease risk equivalent among both men and women: results from a nationwide studyEuropean Journal of Preventive Cardiology, 2014
- Characteristics and Outcome of Patients Hospitalised for Lower Extremity Peripheral Artery Disease in France: The COPART RegistryEuropean Journal of Vascular and Endovascular Surgery, 2010
- Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular EventsThe New England Journal of Medicine, 2008
- Impact of Telmisartan Versus Ramipril on Renal Endothelial Function in Patients With Hypertension and Type 2 DiabetesDiabetes Care, 2007
- International Prevalence, Recognition, and Treatment of Cardiovascular Risk Factors in Outpatients With AtherothrombosisJAMA, 2006
- Angiotensin-Receptor Blockade versus Converting–Enzyme Inhibition in Type 2 Diabetes and NephropathyThe New England Journal of Medicine, 2004
- Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or BothThe New England Journal of Medicine, 2003
- Effects of an Angiotensin-Converting–Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High-Risk PatientsThe New England Journal of Medicine, 2000